CY1121759T1 - Παραγωγα peg που περιεχουν δυο αλυσιδες peg - Google Patents

Παραγωγα peg που περιεχουν δυο αλυσιδες peg

Info

Publication number
CY1121759T1
CY1121759T1 CY20191100651T CY191100651T CY1121759T1 CY 1121759 T1 CY1121759 T1 CY 1121759T1 CY 20191100651 T CY20191100651 T CY 20191100651T CY 191100651 T CY191100651 T CY 191100651T CY 1121759 T1 CY1121759 T1 CY 1121759T1
Authority
CY
Cyprus
Prior art keywords
peg
derivatives containing
chains
polymeric reagents
moiety
Prior art date
Application number
CY20191100651T
Other languages
English (en)
Inventor
J. Milton Harris
Antoni Kozlowski
Samuel P. Mcmanus
Michael D. Bentley
Stephen A. Charles
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of CY1121759T1 publication Critical patent/CY1121759T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33344—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing carbamate group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33331—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group
    • C08G65/33337—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group cyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Παρέχονται πολυμερικά αντιδραστήρια, τα οποία περιέχουν ένα τμήμα αποτελούμενο από άτομα με συγκεκριμένη σειρά, όπου το τμήμα αυτό βρίσκεται μεταξύ ενός υδατοδιαλυτού πολυμερούς και μιας δραστικής ομάδας. Τα πολυμερικά αντιδραστήρια είναι χρήσιμα, μεταξύ άλλων, στο σχηματισμό συμπλοκών πολυμερών- δραστικών ουσιών. Παρέχονται επίσης οι αντίστοιχες μέθοδοι παρασκευής, οι συνθέσεις, τα σκευάσματα και ούτω καθεξής.
CY20191100651T 2003-05-23 2019-06-21 Παραγωγα peg που περιεχουν δυο αλυσιδες peg CY1121759T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47321303P 2003-05-23 2003-05-23
EP04753099A EP1626741A2 (en) 2003-05-23 2004-05-21 Peg derivatives having an amidocarbonate linkage
PCT/US2004/016212 WO2005000360A2 (en) 2003-05-23 2004-05-21 Peg derivatives having an amidocarbonate linkage

Publications (1)

Publication Number Publication Date
CY1121759T1 true CY1121759T1 (el) 2020-07-31

Family

ID=33551443

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100651T CY1121759T1 (el) 2003-05-23 2019-06-21 Παραγωγα peg που περιεχουν δυο αλυσιδες peg

Country Status (22)

Country Link
US (1) US7887789B2 (el)
EP (3) EP2644206B1 (el)
JP (1) JP5048332B2 (el)
KR (1) KR101128320B1 (el)
CN (1) CN1747748B (el)
AU (1) AU2004251602B2 (el)
CA (1) CA2510040C (el)
CY (1) CY1121759T1 (el)
DK (1) DK2644206T3 (el)
EA (1) EA011351B1 (el)
ES (1) ES2725808T3 (el)
HU (1) HUE043911T2 (el)
IL (1) IL169165A (el)
LT (1) LT2644206T (el)
MX (1) MXPA05007628A (el)
NZ (1) NZ541374A (el)
PL (1) PL2644206T3 (el)
PT (1) PT2644206T (el)
SI (1) SI2644206T1 (el)
TR (1) TR201907313T4 (el)
WO (1) WO2005000360A2 (el)
ZA (1) ZA200505157B (el)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101086533B1 (ko) 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
CN1767857A (zh) 2003-02-26 2006-05-03 尼克塔治疗亚拉巴马公司 聚合物－因子ⅷ部分共轭物
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
EP2644206B1 (en) 2003-05-23 2019-04-03 Nektar Therapeutics PEG derivatives containing two PEG chains
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
JP2007513965A (ja) 2003-12-10 2007-05-31 ネクター セラピューティクス アラバマ，コーポレイション ポリマー・活性剤複合体の二つの集団を含む組成物
AU2005222641B2 (en) 2004-03-15 2011-04-07 Nektar Therapeutics Polymer-based compositions and conjugates of HIV entry inhibitors
WO2006005058A2 (en) * 2004-06-30 2006-01-12 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
EP1768700B1 (en) * 2004-07-16 2010-12-15 Nektar Therapeutics Conjugates comprising gm-csf and a polymer
MX2007002441A (es) * 2004-08-31 2007-05-04 Pharmacia & Upjohn Co Llc Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos.
WO2006053299A2 (en) 2004-11-12 2006-05-18 Bayer Healthcare Llc Site-directed modification of fviii
WO2006089228A2 (en) * 2005-02-16 2006-08-24 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
EP1861125A2 (en) * 2005-03-23 2007-12-05 Nektar Therapeutics Al, Corporation Conjugates of an hgh moiety and peg derivatives
WO2006110776A2 (en) 2005-04-12 2006-10-19 Nektar Therapeutics Al, Corporation Polyethylene glycol cojugates of antimicrobial agents
EP1879587A2 (en) * 2005-04-15 2008-01-23 Schering Corporation Methods and compositions for treating or preventing cancer
US8728493B2 (en) * 2005-06-17 2014-05-20 Nektar Therapeutics Polymer based compositions and conjugates of non-steroidal anti-inflammatory drugs
US8568705B2 (en) * 2005-07-18 2013-10-29 Nektar Therapeutics Method for preparing branched functionalized polymers using branched polyol cores
CU23556A1 (es) * 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
EP2364735A3 (en) * 2005-12-16 2012-04-11 Nektar Therapeutics Branched PEG conjugates of GLP-1
CN103030801B (zh) 2006-02-21 2015-07-22 尼克塔治疗公司 嵌段可降解聚合物及由其制备的轭合物
ITMI20060612A1 (it) * 2006-03-30 2007-09-30 Keryos Spa New activaded poly-ethylene glycols-and related polymers and their applications
US9101670B2 (en) 2006-04-07 2015-08-11 Nektar Therapeutics Conjugates of an anti-TNF-α antibody
EP2089052A4 (en) * 2006-05-24 2011-02-16 Peg Biosciences POLYETHYLENE GLYCOL-BASED LINK COMPOUNDS AND BIOLOGICALLY ACTIVE CONJUGATES BASED ON SAID COMPOUNDS
CN101534847A (zh) 2006-08-04 2009-09-16 普罗龙药品公司 修饰型促红细胞生成素
ATE459659T1 (de) * 2006-11-07 2010-03-15 Dsm Ip Assets Bv Carbamat, thiocarbamat oder carbamid mit einer biomolekularen gruppierung
EP2119738B1 (en) * 2007-02-05 2014-04-16 Nippon Shinyaku Co., Ltd. Polyethylene glycol derivative
US20140011964A1 (en) * 2007-02-28 2014-01-09 Serina Therapeutics, Inc. Activated Polyoxazolines and Conjugates and Compositions Comprising the Same
AU2014200906B2 (en) * 2007-03-12 2016-07-07 Nektar Therapeutics Oligomer-protease inhibitor conjugates
JP5448854B2 (ja) * 2007-03-12 2014-03-19 ウェルズ ファーゴ バンク ナショナル アソシエイション オリゴマー−プロテアーゼ阻害剤複合体
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
AU2008317383B2 (en) * 2007-10-23 2013-11-14 Nektar Therapeutics Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom
KR20100095441A (ko) * 2007-11-09 2010-08-30 백스터 인터내셔널 인코포레이티드 변형된 재조합 인자 ⅷ 및 폰 빌레브란트 인자 및 사용 방법
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
EP2262538B1 (en) 2008-03-12 2014-12-10 Nektar Therapeutics Oligomer-amino acid conjugate
US9233165B2 (en) 2008-04-11 2016-01-12 Nektar Therapeutics Oligomer-aryloxy-substituted propanamine conjugates
BRPI0911722B1 (pt) * 2008-07-31 2022-09-13 Pharmaessentia Corp Conjugado de peptídeo-polímero
EP2331140B1 (en) 2008-08-11 2018-07-04 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
US20110195940A1 (en) 2008-09-17 2011-08-11 Nektar Therapeutics Protease Inhibitors Having Enhanced Features
EP2340047A1 (en) * 2008-09-19 2011-07-06 Nektar Therapeutics Polymer conjugates of kiss1 peptides
WO2010033218A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of osteocalcin peptides
WO2010042145A1 (en) * 2008-09-19 2010-04-15 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
WO2010033207A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of therapeutic peptides
US20110171162A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of thymosin alpha 1 peptides
EP2340050A2 (en) * 2008-09-19 2011-07-06 Nektar Therapeutics Polymer conjugates of aod-like peptides
WO2010033223A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of opioid growth factor peptides
WO2010033205A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of v681-like peptides
US20110171312A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use
WO2010033217A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of cd-np peptides
EP2340045B1 (en) * 2008-09-19 2017-04-12 Nektar Therapeutics Polymer conjugates of protegrin peptides
US20110165112A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of c-peptides
US20110318322A1 (en) * 2009-01-12 2011-12-29 Nektar Therapeutics Conjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer
US8785661B2 (en) 2009-05-13 2014-07-22 Nektar Therapeutics Oligome-containing pyrrolidine compounds
EP3461496B1 (en) * 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
RU2554854C9 (ru) 2009-07-31 2017-02-03 Асцендис Фарма Ас Биоразлагаемые нерастворимые в воде гидрогели на основе полиэтиленгликоля
BR112012001988A2 (pt) 2009-07-31 2017-05-09 Sanofi Aventis Deutschland composição de insulina de ação prolongada
AU2010296017C1 (en) 2009-09-17 2013-09-19 Takeda Pharmaceutical Company Limited Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
JP5951496B2 (ja) * 2009-11-18 2016-07-13 ネクター セラピューティクス ポリマー−薬物コンジュゲートの酸性塩形態及びアルコキシル化方法
US8765432B2 (en) * 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
KR20130115086A (ko) 2010-05-17 2013-10-21 세빅스 인코포레이티드 페길화된 c-펩티드
US10040761B2 (en) * 2010-06-25 2018-08-07 Nof Corporation Branched hetero polyethylene glycol and intermediate
ES2661089T3 (es) 2010-07-20 2018-03-27 Halozyme Inc. Métodos de tratamiento o prevención de los efectos secundarios adversos asociados con la administración de un agente anti-hialuronano
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
HUE054318T2 (hu) * 2010-11-12 2021-08-30 Nektar Therapeutics IL-2 molekularész konjugátumai és polimer
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10220020B2 (en) 2010-12-23 2019-03-05 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
WO2012088529A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-sunitinib conjugates
US9943605B2 (en) 2010-12-23 2018-04-17 Nektar Therapeutics Polymer-semaxanib moiety conjugates
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
KR101676543B1 (ko) 2011-06-17 2016-11-15 할로자임, 아이엔씨 히알루로난 분해효소를 이용한 연속적인 피하 인슐린 주입 방법
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
US20180289821A1 (en) * 2011-08-03 2018-10-11 Anp Technologies, Inc. Oxazoline Polymer Compositions and Use Thereof
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
MX342735B (es) 2011-10-24 2016-10-07 Halozyme Inc Diagnostico acompañante para terapia con agente anti-hialuronano y metodos de uso del mismo.
RS59703B1 (sr) 2011-12-30 2020-01-31 Halozyme Inc Varijante ph20 polipeptida, njihove formulacije i upotrebe
DK2833905T3 (en) 2012-04-04 2018-07-30 Halozyme Inc Combination therapy with hyaluronidase and a tumor-targeted taxane
CN102643420B (zh) * 2012-05-09 2015-05-20 中国科学院过程工程研究所 一种异端基双官能团聚烷基醚类化合物及其用途
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014056926A1 (en) 2012-10-11 2014-04-17 Ascendis Pharma A/S Hydrogel prodrugs
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
BR112015014510A2 (pt) 2012-12-21 2017-11-21 Sanofi Sa agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais
EP2947111B1 (en) * 2013-01-17 2018-03-07 Xiamen Sinopeg Biotech Co., Ltd. Monofunctional branched polyethyleneglycol and bio-related substance modified by same
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
CN103980494B (zh) * 2014-04-21 2016-04-13 国家纳米科学中心 一种具有抗肿瘤活性的多肽聚合物及其制备方法和应用
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
HUE043847T2 (hu) 2014-08-28 2019-09-30 Halozyme Inc Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
JP6625627B2 (ja) 2014-10-14 2019-12-25 ハロザイム インコーポレイテッド アデノシンデアミナーゼ−２（ａｄａ２）、その変異体の組成物およびそれを使用する方法
HRP20231732T1 (hr) 2014-11-06 2024-03-15 Pharmaessentia Corporation Režim doziranja pegiliranog interferona
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
ES2826827T3 (es) 2015-06-15 2021-05-19 Angiochem Inc Métodos para el tratamiento de carcinomatosis leptomeníngea
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
SG10202110500TA (en) 2017-06-22 2021-11-29 Catalyst Biosciences Inc Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
KR102542988B1 (ko) * 2018-03-13 2023-06-13 니치유 가부시키가이샤 주쇄 및 측쇄에 단분산 폴리에틸렌 글리콜을 가지는 헤테로이관능성 화합물
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
CA3100204A1 (en) 2018-05-21 2019-11-28 Nektar Therapeutics Compositions of polyethylene glycol conjugates of interleukin-2 and their use to modulate regulatory t cells
US20210261814A1 (en) * 2018-07-20 2021-08-26 Hercules Llc Water soluble or dispersible composition
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
MX2021007843A (es) 2018-12-28 2021-08-11 Vertex Pharma Polipeptidos de activador de plasminogeno, tipo urocinasa, modificados y metodos de uso.
RU2699071C1 (ru) * 2019-04-16 2019-09-03 Федеральное государственное бюджетное образовательное учреждение высшего образования "МИРЭА - Российский технологический университет" Новый полиэтиленгликольсодержащий глицеролипид
JP2022553640A (ja) 2019-10-10 2022-12-26 コディアック サイエンシーズ インコーポレイテッド 眼障害を処置する方法
CA3239501A1 (en) 2021-12-14 2023-06-22 Ali ASHRAFZADEH Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856830A (en) 1971-12-23 1974-12-24 Atlas Chem Ind Polymerizable urethane compounds
US3954584A (en) 1973-06-20 1976-05-04 Kansai Paint Company Photopolymerizable vinylurethane liquid composition
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2632677A1 (de) * 1976-07-16 1978-01-26 Schering Ag Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung
US4180491A (en) 1976-12-01 1979-12-25 Rohm And Haas Company Nonionic polyurethane thickener with surfactant cothickener and organic diluent, clear concentrates, aqueous print pastes, coloring compositions, methods of making and printing
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5290418A (en) 1992-09-24 1994-03-01 Applied Biosystems, Inc. Viscous electrophoresis polymer medium and method
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
CA2207093A1 (en) * 1994-12-06 1996-06-13 Ryan Pharmaceuticals, Inc. Water soluble ubiquinone compositions, prodrugs, and methods relating thereto
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
BR9609006A (pt) 1995-06-07 1999-12-14 Ortho Pharma Corp Peptìdeo, composição farmacêutica, e, processo para tratamento dse paciente.
KR100404774B1 (ko) 1995-09-06 2004-04-01 아사히 덴카 고교 가부시키가이샤 점성조정제
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
PT1019077E (pt) 1997-08-08 2008-02-21 Amylin Pharmaceuticals Inc Novos compostos agonistas de exendina
US6465694B1 (en) * 1998-10-26 2002-10-15 University Of Utah Research Foundation Method for preparation of polyethylene glycol aldehyde derivatives
AU779887B2 (en) 1999-06-08 2005-02-17 La Jolla Pharmaceutical Company Valency platform molecules comprising aminooxy groups
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
ATE317869T1 (de) * 1999-07-14 2006-03-15 Alza Corp Neutrales lipopolymer und liposomale zusammensetzungen daraus
SK5552002A3 (en) 1999-09-28 2003-05-02 Bayer Ag Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
ES2321800T5 (es) 1999-12-22 2017-02-17 Nektar Therapeutics Procedimiento de preparación de ésteres de 1-benzotriazolil carbonato de polímeros solubles en agua
WO2001093914A2 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
JP2002003604A (ja) * 2000-06-21 2002-01-09 Sanyo Chem Ind Ltd 樹脂改質剤
KR100396983B1 (ko) * 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
WO2002060978A1 (fr) 2001-01-30 2002-08-08 Kyowa Hakko Kogyo Co., Ltd. Polyalkylene glycols ramifies
DE10114134A1 (de) 2001-03-19 2002-11-28 Biogenes Verfahren zur Herstellung modifizierter Hydroxypolymere mit einer oder mehreren funktionellen Gruppen und deren Verwendung
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
DE60326224D1 (de) 2002-04-26 2009-04-02 Solexa Inc Signaturen konstanter länge für das parallele sequenzieren von polynukleotiden
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
WO2004044224A2 (en) 2002-11-12 2004-05-27 Enzon Pharmaceuticals, Inc. Branched polymeric prodrugs of vancomycin
US7217845B2 (en) * 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
CN1767857A (zh) * 2003-02-26 2006-05-03 尼克塔治疗亚拉巴马公司 聚合物－因子ⅷ部分共轭物
US7332164B2 (en) * 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
EP2644206B1 (en) 2003-05-23 2019-04-03 Nektar Therapeutics PEG derivatives containing two PEG chains
KR102612902B1 (ko) 2016-04-22 2023-12-18 삼성디스플레이 주식회사 투명 전도막 및 이를 포함하는 전자 소자

Also Published As

Publication number Publication date
CA2510040C (en) 2012-01-03
EP1626741A2 (en) 2006-02-22
ZA200505157B (en) 2006-05-31
EP2644206B1 (en) 2019-04-03
WO2005000360A2 (en) 2005-01-06
NZ541374A (en) 2008-09-26
US7887789B2 (en) 2011-02-15
CN1747748A (zh) 2006-03-15
IL169165A (en) 2011-02-28
EP2644206A2 (en) 2013-10-02
TR201907313T4 (tr) 2019-06-21
EP3593820A1 (en) 2020-01-15
EA011351B1 (ru) 2009-02-27
LT2644206T (lt) 2019-05-27
IL169165A0 (en) 2007-07-04
EA200501863A1 (ru) 2006-06-30
DK2644206T3 (da) 2019-06-11
AU2004251602B2 (en) 2010-05-13
PL2644206T3 (pl) 2019-09-30
PT2644206T (pt) 2019-07-10
CA2510040A1 (en) 2005-01-06
AU2004251602A1 (en) 2005-01-06
MXPA05007628A (es) 2005-10-19
US20050009988A1 (en) 2005-01-13
JP5048332B2 (ja) 2012-10-17
KR101128320B1 (ko) 2012-04-12
HUE043911T2 (hu) 2019-09-30
ES2725808T3 (es) 2019-09-27
JP2007500278A (ja) 2007-01-11
KR20060026845A (ko) 2006-03-24
EP2644206A3 (en) 2014-04-16
SI2644206T1 (sl) 2019-06-28
CN1747748B (zh) 2011-01-19
WO2005000360A3 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
CY1121759T1 (el) Παραγωγα peg που περιεχουν δυο αλυσιδες peg
DE60004172D1 (de) Gcsf konjugate
ATE400352T1 (de) Herstellung von polymergegenständen mit hydrophiler oberfläche
CY1117029T1 (el) Συνεργιστικοι μυκητοκτονοι συνδυασμοι δραστικων ουσιων
CY1108001T1 (el) Παραγωγα μερικα αποθειωμενων γλυκοζαμινογλυκανων προικισμενα με αντι-αγγειογονο δραστηριοτητα και χωρις αντιπηκτικη επιδραση
DE50006269D1 (de) Kombinationen zur einführung von nucleinsäuren in zellen
NO20005809D0 (no) En hepatocyttmålrettet polyetylenglykolpodet polymer poly-L- lysin-genbærer
BR0215142A (pt) Composição polimérica termoplástica, artigos obtidos por modelagem e uso do polìmero
CY1109744T1 (el) Συζυγη και μεθοδοι για την παραγωγη τους, και η χρηση τους για την μεταφορα μοριων δια μεσου βιολογικων μεμβρανων
DE60114599D1 (de) Adehyde enthaltende polymere als nassfestmittel
DE60324435D1 (de) Verfahren zur herstellung von wasserlöslichen polymerderivaten mit terminalen carboxylgruppen
SG155777A1 (en) Glycopegylation methods and proteins/peptides produced by the methods
DK1400551T3 (da) Polyamidkæder med præcis længde og deres konjugater med proteiner
MXPA02012715A (es) Procedimiento para la obtencion de polietilendioxitiofenos neutros, asi como los correspondientes polietilendioxitiofenos.
ES2188007T3 (es) Composiciones acuosas.
MXPA05007165A (es) Reactivos polimericos que comprnden una cetona o un grupo funcional relacionado.
BR0016769A (pt) Composição apropriada para o uso como dispersante de pigmentos, composição de copolìmero de enxerto e dispersão de pigmento
BRPI0506446A (pt) espessante sintético compatìvel colorante para pintura
WO2005005956A3 (en) Fluorophore compounds and their use in biological systems
AU5376500A (en) Functional poly-alpha-aminoacid derivatives useful for the modification of biologically active materials and their application
WO2005060444A3 (en) Hyperbranched segmented copolymers and methods of making same
ATE289863T1 (de) Dispergiermittel
WO1997049718A3 (fr) Conjugues d'un oligonucleotide/polymere conducteur electronique avec une molecule d'interet, et leurs utilisations
BR0015948A (pt) Polìmero de propileno, uso do mesmo, fibra, filme ou peça moldada, e, uso de uma peça moldada
ATE429473T1 (de) Beschichtungszusammensetzung